Sana Biotechnology (SANA), a clinical-stage biotech company specializing in gene and cell therapies, has recently experienced ...

On Tuesday, Sana Biotechnology Inc (SANA) stock saw a decline, ending the day at $2.92 which represents a decrease of $-0.24 or -7.59% from the prior close of $3.16. The stock opened at $3.17 and ...

As researchers push for a type 1 diabetes cure, Sana Biotechnology has provided a nudge forward with new, if limited, ...

We recently compiled a list of the 10 Hottest Smid-Cap Stocks So Far In 2025. In this article, we are going to take a look at ...

Sana Biotechnology Inc (SANA) stock saw a decline, ending the day at $3.49 which represents a decrease of $-0.01 or -0.29% from the prior close of $3.5. The stock opened at $3.41 and touched a low of ...

Sana Biotechnology (NASDAQ:SANA) climbed over 200% on Wednesday following a sharp rally in the post-market yesterday in reaction to a Phase 1 readout for its UP421 cell therapy, which, according ...

Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox.

Since Sana released the data yesterday after market close, the biotech’s stock price has skyrocketed from $1.75 per share to $4.92 as of 10:30 a.m. ET today.

It may be difficult for Sana to protect its technology from the prying eyes of other Pharma and biotech companies, using patents and maintaining a veil of secrecy. For me personally, however ...

Sana’s HIP technology is designed to overcome the immunologic rejection of allogeneic cells. In type 1 diabetes, it also evades the autoimmune rejection of pancreatic beta cells. UP421 cells ...

Bank of America Securities analyst Alec Stranahan maintained a Buy rating on Sana Biotechnology (SANA – Research Report) yesterday and set a ...